NIKKEI 225
40,913.65 +332.89 (+0.82%) HANG SENG
18,028.28 +49.71 (+0.28%) CRUDE OIL
84.06 +0.18 (+0.21%) GOLD FUTURES
2,369.40 0.00 (0.00%) DOW
39,308.00 -23.90 (-0.06%) Bitcoin GBP
45,544.52 -1,690.42 (-3.58%)
HOWL Jul 2024 5.000 put
| Previous close | 1.5500 |
| Open | 1.5500 |
| Bid | 2.4500 |
| Ask | 3.4000 |
| Strike | 5.00 |
| Expiry date | 2024-07-19 |
| Day's range | 1.5500 - 1.5500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswireWerewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
- Data demonstrate that administration of WTX-330 reached therapeutically relevant exposure levels of systemically delivered IL-12 prodrug with an improved tolerability profile over historical data for rhIL-12 - - Early WTX-330 dose-escalation data demonstrated encouraging clinical activity and evidence of immune biomarker activity including an unconfirmed partial response in a metastatic melanoma patient - - Expansion arms open to checkpoint inhibitor-resistant or -naïve relapsed or refractory
- GlobeNewswire
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
- WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy - - Encouraging single agent clinical activity with three objective responses, including a durable confirmed complete response - - Monotherapy recommended dose for expansion selected and expansion arms open for enrollment - - Preliminary data on WTX-124 administered to patients in combination with pembrolizumab showed that the combination was ge
- GlobeNewswire
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside ch
